PDCD1LG2 and neoplasm: Overall, approximately 31% of patients had a tumor specimen with PD-L1 positivity (defined by a PD-L1 CPS ≥1), and 36% of patients had a tumor specimen with PD-L2 positivity (defined by a PD-L2 CPS ≥1).